On April 19th at 11:00 a.m. , we will hold the webinar on “GCP for Investigators. Quality assurance system organization in investigator sites” . Organization of quality system is important for the Sponsors and for the investigator sites. Quality...
On June 18-22nd IPHARMA will visit DIA 2017 Annual Meeting in Chicago, USA. IPHARMA will be presenting its business results for a third year running at the conference. We invite you to visit IPHARMA booth #847 to learn more of our company’s achievements...
On April, 12 IPHARMA took a part in XXIV Russian National Congress “Human and drug” . The congress is the partner of Pharma 2020 Programm and aimed to scientific experience and knowledges exchange. Authentic information expansion is the main...
Since March 27th to April 26th Skolkovo Biotechnology and Medical Cluster, Skolkovo Open University and fundamental medicine faculty hold the educational program “Pharma’s Cool 2017” . The program include innovative and technical experience...
On April 15th at 11:00 a.m. , we will hold the webinar on “GCP for Drug developers (Sponsors). Quality Assurance system organization” . Poorly conducted clinical trials mean the lack of them. Quality and safety is the foundation of the pharmaceutical...
IPHARMA article "5-HT6 Receptor Antagonist as an Adjunct Treatment Targeting Residual Symptoms in Patients With Schizophrenia: Unexpected Sex-Related Effects (Double-Blind Placebo-Controlled Trial)" has been published in the "Journal of Clinical...
On February, 15th at 11:00 a.m., we will hold a webinar on the "Findings during the inspections of Federal Service for Surveillance in Healthcare (Roszdravnadzor) in 2016" . Register to the webinar What will we discuss during the webinar? ...
On January, 25th at 11:00 am, we will hold a webinar on the “Project management on start-up of clinical trial”. Register to webinar What will we discuss during the webinar? • The specifics of project management on start-up stage...
On November, 9-10th, IPHARMA took part in VIIth Russian Congress of Patients . The problems of healthcare development, availability of drugs, quality of medical care and safety of patients have been discussed during the roundtable meetings and panel discussions...
On November, 9th, IPHARMA took part in roundtable discussions at VIIth Russian Congress of Patients . The Congress has been conducted by Russian Patients Association since 2010. It is a unique platform for the dialogue between non-profit organizations for...
On November, 16 th , at 11:00 am, we will hold a webinar on the “Highlights of the next-in-class drugs development”. The development of pharmacologically similar agents and improved analogues of innovative drugs (next-in-class) is one of the...
On November 8-10th, IPHARMA will take a part in the "Clinical trials in Russia" Adam Smith Forum which is the main event of the year in the clinical trials field. As in previous years, IPHARMA has become a sponsor of this event and will report...
On October, 26-28th, IPHARMA took part in the "Open innovations" Forum which was held in Skolkovo Technopark. IPHARMA’s stand was located in the showroom №14, where all the members of biopharmaceutical field could learn more about our company...
IPHARMA has become an academic partner at the SkinHack event which will be held on November, 9-13th in Skolkovo Innovation Centre. The Hackathon applies methods of the machine vision, machine learning and artificial intelligence to analyze images and videos...
In 2016 IPHARMA signed scientific cooperation agreement with the I.M.Sechenov First Moscow State Medical University in which specialists of the company will participate in educational and research projects making educational materials and more. In October...
In October, 19th, at 11:00 AM, we will lead the webinar “Clinical trials in oncology introduction”. Register to the webinar What will we discuss at the webinar? Special aspects of clinical trials in oncology What you should pay attention...
On September, 28th, at 11:00 am, we will hold a webinar on the "Rules of granting subsidies to implement the projects on drug development under the "Pharma 2020" Federal Target Program”. Register to the webinar The webinar is devoted...
Since September 28th, IPHARMA will continue to hold a series of webinars in order to provide information to the vast media audience on variousaspects of clinical trials conduct. The company has an extensive experience in conducting trainings for the staff...
On September 12, 2016, IPHARMA was authorized by the Ministry of Health of the Russian Federation to conduct the Phase IIa clinical trial of the medicinal product VM-1011. Protocol № HBV-VM1011-02 «A partially-blind randomized comparative pilot clinical...
IPHARMA company celebrated 4th Birthday on September 8. Traditional picnic was on the territory of Technopark Skolkovo. We had a good time in a friendly and fun atmosphere by the lake. Our regular guest Big Jazz Orchestra performed the hits of The Beatles and...
In August 2016, IPHARMA LLC was authorized by the Ministry of Healthcare of the Russian Federation to conduct the Phase I clinical trial of medicinal product ИД 4025. Protocol № HCV-ИД4025-04 «Double-blind randomized placebo-controlled study to evaluate...
We congratulate and are proud of Evgenia Ezhova, IPHARMA Project Manager, for the 3d team place in Russian Championship on Endurance horse rides for 80 km. International tournament Russian Championship was held in Spassk-Ryazansky, the Ryazan region, on...
Each year IPHARMA takes part in DIA (Drug Information Association) Global Conferences in Europe and the USA. During the event, participants share their views and knowledge and establish international contacts with potential partners and clients, which leads...
We are pleased to invite you to DIA 2016 52st Annual Meeting, which takes place in Pennsylvania Convention Center, Philadelphia, PA, June 26-30, 2016. Our booth number is 644. Natalia Vostokova, IPHARMA Chief Operating Officer, will present a poster on the...
Moscow, Russia, January 2014. "TheraMAB" LLC. announces the beginning of multicenter Phase Ib/IIa clinical trial of multiple TAB08 i.v. administration. This is “first-in-class” anti-CD28 humanized mAb of IgG4 type for the treatment...